The BRG mouse model has been refined over the years, giving rise to a state-of-the-art BRGS (BALB/c Rag2-/- IL-2Rγc-/- SIRPα.NOD) immuno-deficient mouse strain. The model portfolio of AXENIS is based on its proprietary state-of-the-art, immuno-deficient BRGS mouse model, which is particularly permissive to the long-term establishment of a human xenograft.
These BRGS-HIS mice contain all major human hematopoietic cell subsets, such as B cells, T cells (including CD4+ Treg cells), NK cells, and the myeloid compartment including dendritic cells (DCs), plasmacytoid cells (pDCs) and monocytes / macrophages. The human myeloid compartment can be boosted with a simple exogenous Flt3-ligand treatment in BRGS mice lacking the corresponding mouse receptor (Flk2/Flt3). The boost of human dendritic cell accumulation in this novel model called BRGSF (BALB/c Rag2tm1Fwa IL-2Rγ tm1Cgn SIRPαNOD Flk2tm1Irl) potentiate human T cell function.
These new generations of humanized mice BRGS and BRGSF, facilitate translational research in several biomedical disciplines and approaches